<DOC>
	<DOC>NCT02949778</DOC>
	<brief_summary>Double blinded, randomized, controlled, phase IV intervention trial. Both groups will receive a quadratus lumborum Block (QL), using ropivacaine 3.75 mg/mL in the intervention group, and sterile sodium chloride in the control group. The aim of study is to investigate the effect of a QL Block on the perioperative pain during postbariatric abdominoplasty.</brief_summary>
	<brief_title>Quadratus Lumborum Block for Abdominoplasty</brief_title>
	<detailed_description />
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Ropivacaine</mesh_term>
	<criteria>American Society of Anesthesiologists Physical Classification Status (ASA) III Age 18 to 64 Weight above or equal to 60 kg Scheduled for postbariatric surgery with standard full abdominoplasty performed by Dr Fr√∏yen Patient is expected able to cooperate during the treatment and follow up. Signed informed consent obtained and documented according to the International Conference on Harmonization (ICH) good clinical practice (GCP), and national/local regulations. A history of anaphylactic shock Cardiovascular disease other than hypertension and/or hyperlipidemia Known allergy to ropivacaine or morphine A history of chronic pain Psychiatric comorbidity Scheduled opioid pain medication or neuroleptic drugs Coagulation disorders or treatment with platelet inhibitors Pregnancy or breastfeeding Treatment with class III antiarrhythmics, sertindole, ziprasidone, amisulpride, ceritinib, hydroxyzine, fluvoxamine Any medical contraindication to the study intervention by the attending anaesthetist or surgeon (to be specified in screening form).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>